sanjeri / iStockphoto.com
BMS’s teams are working to answer key questions and more intimately understand the interplay between the immune system and cancer, Paul Golian, vice president and assistant counsel of IP at BMS, tells LSIPR.
Being part of a team that “discovers, develops, and delivers” transformational medicine is one of the reasons that Paul Golian’s job at Bristol-Myers Squibb (BMS) is so rewarding. Another is meeting patients that have benefited from the drugs he has worked on, something that makes him particularly proud.
As vice president and assistant counsel of IP at BMS, New-York based Golian plays a pivotal role in protecting the company’s new therapies.
“My team and I are laser-focused on protecting BMS’s innovations,” he tells LSIPR. This encompasses patent procurement, freedom to operate counselling, negotiating and managing IP provisions in agreements, and patent enforcement.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
LSIPR 50 2018, Paul Golian, BMS, Bristol-Myers Squibb, innovation, biology